Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

58.92 -0.32 (-0.54%)
Streaming Delayed Price Updated: 10:46 AM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,848
Open 59.23
Bid (Size) 58.91 (2)
Ask (Size) 59.05 (4)
Prev. Close 59.24
Today's Range 58.89 - 59.39
52wk Range 32.83 - 65.53
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO is showing good growth, while it is not too expensive. 
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. 
Via Chartmill

Performance

YTD
+57.58%
+57.58%
1 Month
+5.08%
+5.08%
3 Month
+15.17%
+15.17%
6 Month
+43.01%
+43.01%
1 Year
+57.12%
+57.12%

More News

Read More
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
Via Benzinga
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Via Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Via Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
Via Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
Via Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
Via Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Via InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
Via InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.